Department of Growth and Reproduction, Rigshospitalet and Copenhagen University, DK-2100 Copenhagen, Denmark.
J Clin Endocrinol Metab. 2012 Aug;97(8):E1540-9. doi: 10.1210/jc.2012-1388. Epub 2012 May 17.
Most previous studies of 45,X/46,XY mosaicism are case reports or have described single aspects of the disease.
The objective was to provide longitudinal data of patients with 45,X/46,XY mosaicism.
This was a retrospective, longitudinal study conducted from June 1990 to January 2012.
The study took place at a tertiary pediatric and andrological referral center.
Twenty-five patients (18 boys, seven girls) with 45,X/46,XY mosaicism and its variants were included and were compared to healthy controls.
INTERVENTION(S): No interventions were included in the study.
MAIN OUTCOME MEASURE(S): Phenotypes were scored using external masculinization scores. Serum LH, FSH, testosterone, estradiol, and inhibin B levels were reported in male patients. IGF-I levels and height were reported in all patients. Available biopsies/gonadectomies were histologically examined.
Fourteen of 18 males had external masculinization scores consistent with normal virilization. Ten of 11 male patients experienced spontaneous puberty. Median height sd score was -2.0 (range, -3 to 0.3) for males and -2.2 (range, -2.5 to -1.4) for females, both considerably below genetic potential. Median 1-yr height gain after GH treatment in seven patients was 0.5 sd (0.1 to 1.2). All tissue samples from 15 patients (eight males, seven females) revealed abnormal gonadal histology. Four patients had carcinoma in situ (CIS); two had tissue samples available from early childhood, one showing CIS.
Gonadal function in most 45,X/46,XY males, even those with genital ambiguity, seems sufficient for spontaneous puberty. Short stature and 45,X/46,XY mosaicism seem associated, but patients appear to benefit from GH treatment. Histology from two patients with biopsies from early childhood indicates that CIS originates before puberty.
大多数先前对 45,X/46,XY 嵌合体的研究都是病例报告或仅描述了该疾病的单一方面。
本研究旨在提供 45,X/46,XY 嵌合体患者的纵向数据。
这是一项回顾性、纵向研究,于 1990 年 6 月至 2012 年 1 月进行。
研究在一家三级儿科和男科转诊中心进行。
纳入了 25 名(18 名男孩,7 名女孩)患有 45,X/46,XY 嵌合体及其变体的患者,并与健康对照组进行了比较。
本研究未包括任何干预措施。
使用外部男性化评分对表型进行评分。报告了男性患者的血清 LH、FSH、睾酮、雌二醇和抑制素 B 水平。报告了所有患者的 IGF-I 水平和身高。对可用的活检/性腺切除术进行了组织学检查。
18 名男性中有 14 名的外部男性化评分符合正常男性化。11 名男性中有 10 名自发进入青春期。男性的平均身高标准差评分为-2.0(范围-3 至 0.3),女性为-2.2(范围-2.5 至-1.4),均远低于遗传潜能。7 名患者在接受 GH 治疗后的 1 年身高增长率中位数为 0.5 标准差(0.1 至 1.2)。15 名患者(8 名男性,7 名女性)的所有组织样本均显示异常性腺组织学。4 名患者患有原位癌(CIS);其中 2 名患者有来自早期儿童的组织样本,其中 1 名显示 CIS。
大多数 45,X/46,XY 男性(即使有生殖器模糊)的性腺功能似乎足以自发进入青春期。身材矮小和 45,X/46,XY 嵌合体似乎相关,但患者似乎受益于 GH 治疗。两名患者的活检组织来自早期儿童,表明 CIS 起源于青春期之前。